Needham & Company Upgrades ResMed (RMD) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Resmed, Inc. (RMD) Tops Q2 EPS by 2c
January 22, 2015 4:12 PM ESTResmed, Inc. (NYSE: RMD) reported Q2 EPS of $0.64, $0.02 better than the analyst estimate of $0.62. Revenue for the quarter came in at $423 million versus the consensus estimate of $408.2 million.
"We are pleased to report strong double-digit revenue growth, demonstrating excellent progress with our new product launches," said Mick Farrell, ResMed's chief executive officer. "We achieved robust commercial performance across all regions, including... More
